Lessons learned in the face of new health challengesSARS-COV-2 exposed our vulnerability and strategic weakness at European level, in terms of biotechnological manufacturing capacity. more ➔
Innate immunity and its power in cancer therapyOne of the most distinguishing hallmarks of tumours is their ability to avoid immune recognition. New immunotherapies have focused on breaking down those barriers, leading to treatment breakthroughs … more ➔
Pharma industry on expansion courseAt the CPHI, the world’s largest pharmaceutical event, which attracted 40,405 visitors this year, it became evident that the COVID-19 pandemic has had an extremely positive impact on the (bio)pharmaceutical … more ➔
Blow-Fill-Seal technology and vaccine deliveryUnit-dose?The SARS-CoV2 pandemic caused 6.3 million deaths and contaminated 545 million people across the world. In spite of the rapid development and approval of vaccines, the shortages of consumables … more ➔
Making a better cheeseThe French company Standing Ovation uses precision fermentation to create the protein that gives cheese its unique properties. With his pitch, co-founder and CEO Frédéric P’ques took the prize at the … more ➔
AGC Biologics doubles mammalian capacityWith a new expansion coming online in Copenhagen, AGC Biologics is offering more capacity in Europe for mammalian biologics projects using innovative single-use bioreactor technology. This is the latest … more ➔
Unleashing the power of LNP encapsulationThe Covid-19 pandemic has changed perception of the value of rapid vaccine production, followed by multi-billion investments across the globe. While nanomedicines are receiving attention for enhancing … more ➔
Cells: The heart of Biovian’s rAAV manufacturingViral Vectors?Commercial-scale manufacturing demands a high yield of potent rAAV products. Understanding the metabolism during cell growth, especially at high densities, molecular effects of transfection … more ➔
Vector BioPharma: the future of gene deliveryPrecision gene delivery remains one of the greatest challenges in modern medicine. A Basel-based biopharma company, Vector BioPharma, has accepted the challenge and, with cutting-edge technology from … more ➔
Crossing the commercialisation chasmAs a late-stage investor focusing on the European bioeconomy, the ECBF is carefully assessing the maturity of any technology, but more important than maturity is the ability to reach commercial scale. … more ➔
